Lei Xin

NovoBoard evaluates de novo peptide sequencing methods using benchmark datasets and FDR estimation to assess accuracy and significance of peptide-spectrum matches.

This study introduces DeepNovo Peptidome and DeepSelf for neoantigen discovery and validation using immunopeptidomics and deep learning, demonstrating their application in cervical cancer tissues.

The paper introduces a personalized deep learning workflow to identify neoantigens from mass spectrometry data, improving accuracy and discovery rates in melanoma patients.